Michel Bouvier is a world-renowned expert in cell signaling and molecular pharmacology who has made significant breakthroughs in the field of G protein-coupled receptors (GPCRs). His trailblazing work on the regulatory mechanisms of this vast family of cellular receptors has given rise to new concepts essential to advancing health research and the treatment of many medical conditions and illnesses.
Currently Professor in the Department of Biochemistry and Molecular Medicine and CEO of the Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal, Michel Bouvier is a Fellow of the Canadian Academy of Health Sciences and the Royal Society of Canada. His leadership at IRIC has had a major influence on the exchange of research between the academic and industrial fields, fostering models to encourage ongoing collaboration between both areas for their mutual advancement and to the benefit of wider society. In 2017, the Quebec government awarded him the Wilder-Penfield Prize, its highest honour in biomedical research.
Bouvier’s invaluable contributions include his development of analytical tools that he’s shared widely with the scientific community to further research in other areas. In particular, his development and popularization of the Bioluminescence Resonance Energy Transfer technique has helped researchers across the globe by offering a sophisticated tool for the real-time analysis of protein-protein interactions and signal transduction in living cells. Leading a team of researchers at the IRIC, Michel Bouvier continues to work towards new methodologies for drug development. His ongoing scientific research is shifting paradigms and advancing knowledge in the fields of physiology, pharmacology, and medicine—and it will have significant, long-lasting implications in the development of new strategies for personalized therapeutic interventions.
Photo credit: Christian Charbonneau
The FutureEconomy.ca had the opportunity to talk with Dr. Bouvier – video with interview below. You can also listen to the podcast here.
